AI주식인사이트AI Stock Insight
B

바이오노트

377740KOSPI

57.9 / 100

Reference Date: 2026-09-08

Financial Score24.5 / 40
News Sentiment15.4 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 1.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BIONOTE is a company established in 2003 specializing in animal diagnostic products and bio-content, leveraging its proprietary recombinant antigen and antibody technology to develop and manufacture rapid immunodiagnostic, enzyme-linked immunosorbent assay (ELISA), and related products. Key offerings include the BIONOTE Rapid and Vcheck F brands, used in veterinary clinics and farms, with expansion into human in vitro diagnostic (IVD) raw material supply.

Number of Employees

334people

Average Salary

49.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.32Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
-5.56Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
2.09Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.6% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲81.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.1% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 2Negative 0Average Sentiment Score 61.7

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 4,780Won52-week high 6,23052-week low 4,365
1-month return3.0Point

1m -1.34% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-13